|
|
|
|
|
Product Name
|
Kallikrein 10 peptide (Catalytic domain)
|
|
Product type
|
Proteins and Peptides
|
|
Peptide
|
This peptide was used as an immunogen for ab40956 - Kallikrein 10 antibody - Catalytic domain.
|
|
Specificity
|
We have a range of domain specific antibodies for this target. For a full list please see all Kallikrein 10 antibodies
|
|
Tested applications
(see key)
|
ELISA, WB
|
|
Application notes
(see key)
|
Recommended dilutions
ELISA: Use at an assay dependent dilution. WB: Use at an assay dependent dilution. This peptide can be used with studies using ab40956. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
|
|
Research areas
|
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Serine protease >> Kallikreins
Cancer >> Invasion/microenvironment >> ECM >> Extracellular matrix >> Kallikreins
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> Kallikreins
|
|
Relevance
|
Kallikrein 10, also known as normal epithelial cell specific-1 (NES1) and protease serine-like 1 (PRSSL1), is a trypsin-like serine proteinase. Originally described from a subtractive library looking for genes that were down-regulated in breast cancer, kallikrein 10 was thought to be epithelial cell specific. Kallikrein 10 is reported to be up regulated in pancreatic cancer and ovarian cancer, but down regulated in testicular cancer and breast cancer, perhaps due to differential hormonal regulation, or tissue specificities. Breast cancer patients that had elevated kallikrein 10 had a worse prognosis, leading to speculation that kallikrein 10 might be protective in breast cancer, similar to the argument put forth for kallikrein 3 in prostate cancer. Kallikrein 10 is found in high levels in the pancreas and in lower levels in the tonsils, esophagus, skin, brain, testis and ovary. Biological fluids (breast milk, serum, seminal plasma, urine) contain kallikrein 10, the highest levels found in milk. The cerebral spinal fluid (CSF) contains Kallikrein 10, and was reported to be elevated in patients with Alzheimer’s disease. Endogenous inhibitors include kallistatin, protein-C inhibitor and 1-proteinase inhibitor, although Kallikrein 10 can be found complexed to a number of different proteinase inhibitors.
|
|
|
Kallikrein 10 peptide (Catalytic domain) (ab43092) |
|
Purity
|
>95% by SDS-PAGE
|
|
Storage buffer
|
Preservative: None
Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75
|
|
Form
|
Liquid
|
|
Concentration
|
1.000 mg/ml
|
|
Storage instructions
|
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
|
| |
At Abcam, we have one centralized database to hold all of our product information, so that everything we know about this Kallikrein 10 peptide (Catalytic domain) is on this datasheet. But please do contact us if you would like any reassurance! |
 |
|
| |
|
Search PubMed (MEDLINE) for references to Kallikrein 10
|
| |
Kallikrein 10 peptide (Catalytic domain) - more information
|
Customer reviews (feedback) regarding Kallikrein 10 peptide (Catalytic domain) |
Customer FAQs regarding Kallikrein 10 peptide (Catalytic domain) |
Protocols for Kallikrein 10 peptide (Catalytic domain) |
Price and availability of products related to Kallikrein 10 peptide (Catalytic domain) |
| |
Kallikrein 10 peptide (Catalytic domain) - related products:
|
|
|
| |
Kallikrein 10 peptide (Catalytic domain) - other tools:
|
Contact Abcam with a Technical Enquiry about Kallikrein 10 peptide (Catalytic domain) |
| |
All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Pricing information loading
